Barclays Portfolio holdings
Barclays PLC, founded in 1690 by goldsmith bankers in London, is a British multinational financial institution headquartered in London, operating as one of the world’s oldest banks with a significant presence in investment banking, retail banking, and wealth management. Managing billions in assets, Barclays serves millions of customers globally through its retail arm (notably in the UK) and its investment banking division, which excels in trading, mergers and acquisitions, and capital markets, competing with Wall Street giants. The bank has navigated challenges like the 2008 financial crisis—opting for private funding over a government bailout—and has since focused on restructuring, digital innovation, and sustainable finance initiatives. With a rich history and a modern global footprint, Barclays remains a key player in both UK and international financial markets.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
State Street SPDR S&P 500 ETF Trust
SPY
|
+$637M |
| 2 |
Weyerhaeuser
WY
|
+$340M |
| 3 |
IQVIA
IQV
|
+$132M |
| 4 |
Halliburton
HAL
|
+$123M |
| 5 |
Dover
DOV
|
+$112M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Invesco QQQ Trust
QQQ
|
+$3.68B |
| 2 |
State Street Consumer Discretionary Select Sector SPDR ETF
XLY
|
+$708M |
| 3 |
State Street Health Care Select Sector SPDR ETF
XLV
|
+$460M |
| 4 |
RAI
Reynolds American Inc
RAI
|
+$293M |
| 5 |
Gilead Sciences
GILD
|
+$246M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 6.22% |
| 2 | Healthcare | 5.12% |
| 3 | Financials | 4.53% |
| 4 | Consumer Discretionary | 4.09% |
| 5 | Communication Services | 3.16% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
3826
WEX
WEX
$6.32B
| $378K | ﹤0.01% |
3,361
-571
| -15% | -$61.9K |
|
3827
CALL
Hartford Financial Services
HIG
$39.2B
| $377K | ﹤0.01% |
6,800
-57,300
| -89% | -$3.12M |
|
|
AYR
3828
DELISTED
Aircastle Ltd
AYR
| $377K | ﹤0.01% |
16,895
+8,193
| +94% | +$182K |
|
|
CALA
3829
DELISTED
Calithera Biosciences, Inc
CALA
| $376K | ﹤0.01% |
1,193
+418
| +54% | +$132K |
|
|
FLOW
3830
DELISTED
SPX FLOW, Inc.
FLOW
| $376K | ﹤0.01% |
9,760
-39,372
| -80% | -$1.39M |
|
3831
Morningstar
MORN
$7.53B
| $374K | ﹤0.01% |
4,405
-1,145
| -21% | -$93.3K |
|
3832
CALL
Ecolab
ECL
$79.8B
| $373K | ﹤0.01% |
2,900
+2,800
| +2,800% | +$368K |
|
3833
CALL
Papa John's
PZZA
$805M
| $373K | ﹤0.01% |
5,100
+4,100
| +410% | +$308K |
|
|
HK.WS
3834
DELISTED
Halcon Resources Corporation
HK.WS
| $372K | ﹤0.01% |
676,281
| – | – |
|
3835
Accuray
ARAY
$34.2M
| $370K | ﹤0.01% |
92,392
+84,587
| +1,084% | +$363K |
|
3836
Maximus
MMS
$3.11B
| $369K | ﹤0.01% |
5,724
+1,094
| +24% | +$67.1K |
|
3837
Energous
WATT
$102M
| $369K | ﹤0.01% |
49
-40
| -45% | -$313K |
|
|
YRD
3838
Yiren Digital
YRD
$109M
| $369K | ﹤0.01% |
8,800
+8,782
| +48,789% | +$329K |
|
|
WDR
3839
DELISTED
Waddell & Reed Financial, Inc.
WDR
| $369K | ﹤0.01% |
18,359
-11,966
| -39% | -$230K |
|
3840
First Busey Corp
BUSE
$2.57B
| $368K | ﹤0.01% |
11,753
-85
| -0.7% | -$2.48K |
|
3841
PUT
Entergy
ETR
$50B
| $367K | ﹤0.01% |
9,600
+3,000
| +45% | +$116K |
|
3842
Pampa Energía
PAM
$4.41B
| $366K | ﹤0.01% |
5,615
-4,147
| -42% | -$243K |
|
3843
CALL
Sempra
SRE
$55B
| $365K | ﹤0.01% |
6,400
-2,800
| -30% | -$162K |
|
|
ITCI
3844
CALL
DELISTED
Intra-Cellular Therapies Inc.
ITCI
| $365K | ﹤0.01% |
+23,100
| New | +$339K |
|
|
AMED
3845
DELISTED
Amedisys
AMED
| $364K | ﹤0.01% |
6,513
-16,285
| -71% | -$861K |
|
3846
PUT
ProShares UltraShort S&P500
SDS
$390M
| $364K | ﹤0.01% |
312
+308
| +7,700% | +$376K |
|
3847
Alaunos Therapeutics
TCRT
$4.76M
| $364K | ﹤0.01% |
395
+391
| +9,775% | +$347K |
|
|
ZNGA
3848
PUT
DELISTED
ZYNGA INC. CL A COMMON
ZNGA
| $364K | ﹤0.01% |
96,300
+20,200
| +27% | +$74.4K |
|
3849
Teekay
TK
$985M
| $363K | ﹤0.01% |
40,649
-21,949
| -35% | -$192K |
|
|
CAVM
3850
CALL
DELISTED
Cavium, Inc.
CAVM
| $363K | ﹤0.01% |
5,500
+4,800
| +686% | +$304K |
|
Similar funds
Barclays's Q3 2017 Portfolio in Review
As of Q3 2017, Barclays held 7,380 positions worth $97.1B, up 4% from $93.4B the previous quarter. Its ten largest holdings account for 29% of the portfolio.
Barclays's Q3 2017 filing shows 424 new, 3,249 increased, 2,816 reduced and 405 closed positions. Its largest new stake was Crown Castle International Corp. 6.875% Mandatory Convertible Preferred Stock, Series A: 39,656 shares worth $42.4M. The largest sale was Invesco QQQ Trust, an estimated $3.68B.
By sector, the portfolio is most concentrated in Technology at 6.2% of assets, up from 6.1% a quarter earlier, followed by Healthcare and Financials.
- Barclays's largest Q3 2017 buy was Crown Castle International Corp. 6.875% Mandatory Convertible Preferred Stock, Series A: 39,656 shares worth $42.4M.
- Barclays added most to State Street SPDR S&P 500 ETF Trust in Q3 2017, an estimated $637M increase.
- Barclays's biggest Q3 2017 reduction was Invesco QQQ Trust, cutting an estimated $3.68B.
- Barclays fully exited Reynolds American Inc in Q3 2017, selling an estimated $293M.
- Barclays's ten largest holdings make up 29% of its $97.1B portfolio in Q3 2017.
- Barclays opened 424 new positions and closed 405 in Q3 2017.
- Barclays's portfolio value rose 4% quarter-over-quarter to $97.1B.
Based on Barclays's 13F filing for Q3 2017, filed 14 Nov 2017.